Worry over drug-resistant TB

July 2, 2012 By Chuck Leddy
Worry over drug-resistant TB
The disease is mistakenly viewed as a problem of poverty. “TB doesn’t discriminate; anyone can get it,” said panelist Khisimuzi Mdluli (right). The symposium, moderated by Barry Bloom, focused on the reasons for the emergence of drug-resistant TB and what can be done to remedy this growing crisis. Among the panelists was Sarah Fortune (left), the Melvin J. and Geraldine L. Glimcher Assistant Professor of Immunology and Infectious Diseases at the Harvard School of Public Health. Credit: Jon Chase/Harvard Staff Photographer

On the same day that the U.S. Supreme Court upheld the national health care law, medical researchers from around the globe gathered at the Broad Institute of Harvard and MIT for the annual New England Tuberculosis Symposium. The focus of the all-day event was a disturbing global health trend: the emergence of a form of incurable tuberculosis that is drug-resistant.

The highlight of Thursday’s symposium was an eight-member panel, moderated by Barry Bloom, that focused on the reasons for the emergence of drug-resistant TB, especially in poorer nations such as India, and what can be done to remedy this growing crisis. Bloom is a Harvard University Distinguished Service Professor and the Joan L. and Julius H. Jacobson Professor of Public Health at the Harvard School of Public Health.

Khisimuzi Mdluli from TB Alliance, a global nonprofit working against the disease, spoke repeatedly about the need to develop new drugs to combat tuberculosis. Since the 1960s, two drugs — isoniazid and rifampicin — have been the standard TB treatment. “We need more choices,” said Mdluli, “so if people don’t respond to the first [treatment] regimen, what can we do next? We don’t have good answers.”

According to the World Health Organization, millions of people (8.8 million in 2010) contract tuberculosis each year, and about a million die from it. Mdluli called for more mobilization around fighting TB, urging a coordinated public awareness campaign similar to the one waged around HIV.

The disease, he says, is mistakenly viewed as a problem of poverty. “TB doesn’t discriminate; anyone can get it,” he said. When asked by Bloom what is needed to foster the development of new drugs, Mdluli replied: “money, money, money.”

Epidemiologist Bob Horsburgh of Boston University seconded Mdudli’s assertion that TB attacks the poor and rich alike. “We need to convince the upper classes that they are at risk too, because they really are,” he said. “It’s not uncommon [in places like India] for a lower-class household worker to spread TB to the whole [upper-class] household.”

One of the main problems in detecting, and thus treating, tuberculosis, the panelists agreed, is the public stigma attached to having the disease. Sarah Fortune, the Melvin J. and Geraldine L. Glimcher Assistant Professor of Immunology and Infectious Diseases at the Harvard School of Public Health, detailed how crucial early detection can be in treating TB, explaining that educating people about better treatment options can help remove any stigma and thus help early detection efforts.

Zarir Udwadia, a doctor and TB specialist at Hinduja National Hospital in Mumbai, India, described the rising stress that drug-resistant is placing on India’s already-overstretched health care system. “In India,” said Udwadia, “the system is lousy; people don’t want to go there,” so they go to private health providers, who are largely unregulated.

He called for a public-private partnership in India, where “TB might be diagnosed in the private sector, and then patients could get treatment in the public sector.”

The panel also included Jeremy Greene, Harvard assistant professor in the history of science and instructor at Harvard Medical School (HMS); Scott Podolsky, assistant professor of and social medicine at HMS and director of the Center for the History of Medicine; and Rob Warren of Stellenbosch University in Cape Town, South Africa.

The panelists agreed that more resources needed to be placed on treating drug-resistant TB. Horsburgh summed up the issue: “We’ve had the tools to cure TB for 40 years now. Why have we failed? We lacked the political will to do it. We need to do what AIDS activists have done to raise awareness” for a cure.

The was a step in that direction. Early in the session, Bloom told the panel that he’d recently been asked by India’s prime minister to serve as an adviser in that nation’s search for a new minister. Bloom garnered laughter from the panel and the audience when he described the discussion as “a job interview” for each of them.

Explore further: Indian experts probing 'untreatable' TB cases

Related Stories

Indian experts probing 'untreatable' TB cases

January 17, 2012
The Indian government on Tuesday dispatched a team of medical experts to the financial capital, Mumbai, to assess reports of a handful of cases of apparently untreatable tuberculosis.

Drug-resistant TB blamed on Indian treatment flaws

March 23, 2012
(AP) -- India's inadequate government-run tuberculosis treatment programs and a lack of regulation of the sale of drugs that fight it are responsible for the spiraling number of drug-resistant cases that are difficult to ...

Vanderbilt study leads to simpler therapy for treating latent tuberculosis

December 9, 2011
Research, led by Timothy Sterling, M.D., professor of Medicine at Vanderbilt University Medical Center, has led to an important change in CDC recommendations in the regimen for prevention of the centuries-old scourge, tuberculosis ...

Management of TB cases falls short of international standards

February 9, 2012
The management of tuberculosis cases in the European Union (EU) is not meeting international standards, according to new research.

S.Africa conducts trials for shorter TB treatment

March 30, 2012
South African researchers said Friday they were conducting medical trials to shorten the duration of tuberculosis treatment to make it easier for patients to complete the full regimen.

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.